- Home
- SLDP vs ATAI Comparison
SLDP vs ATAI Comparison
Compare SLDP & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLDP
- ATAI
- Stock Information
- Founded
- SLDP 2011
- ATAI 2018
- Country
- SLDP United States
- ATAI Germany
- Employees
- SLDP N/A
- ATAI N/A
- Industry
- SLDP Electrical Products
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- SLDP Energy
- ATAI Health Care
- Exchange
- SLDP Nasdaq
- ATAI Nasdaq
- Market Cap
- SLDP 230.9M
- ATAI 214.8M
- IPO Year
- SLDP N/A
- ATAI 2021
- Fundamental
- Price
- SLDP $1.29
- ATAI $1.24
- Analyst Decision
- SLDP Buy
- ATAI Strong Buy
- Analyst Count
- SLDP 4
- ATAI 4
- Target Price
- SLDP $2.75
- ATAI $9.00
- AVG Volume (30 Days)
- SLDP 1.6M
- ATAI 1.3M
- Earning Date
- SLDP 11-07-2024
- ATAI 11-13-2024
- Dividend Yield
- SLDP N/A
- ATAI N/A
- EPS Growth
- SLDP N/A
- ATAI N/A
- EPS
- SLDP N/A
- ATAI N/A
- Revenue
- SLDP $18,026,000.00
- ATAI $331,000.00
- Revenue This Year
- SLDP $2.53
- ATAI $93.15
- Revenue Next Year
- SLDP $95.43
- ATAI N/A
- P/E Ratio
- SLDP N/A
- ATAI N/A
- Revenue Growth
- SLDP N/A
- ATAI N/A
- 52 Week Low
- SLDP $1.00
- ATAI $1.03
- 52 Week High
- SLDP $2.35
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- SLDP 47.64
- ATAI 38.50
- Support Level
- SLDP $1.05
- ATAI $1.47
- Resistance Level
- SLDP $1.23
- ATAI $1.69
- Average True Range (ATR)
- SLDP 0.05
- ATAI 0.11
- MACD
- SLDP 0.00
- ATAI -0.05
- Stochastic Oscillator
- SLDP 33.33
- ATAI 0.95
About SLDP Solid Power Inc.
Solid Power Inc is engaged in developing all-solid-state battery cell technology to enable the next generation of batteries for the EV and other markets. The company's planned business model is to license its all-solid-state battery cell designs and manufacturing know-how to top tier battery manufacturers or automotive original equipment manufacturers and to sell its sulfide-based solid electrolyte for incorporation into all-solid-state battery cells.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.